Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download. Long heralded as an innovation powerhouse able to hold its own against the…
Switzerland Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing attractiveness of Switzerland as a pharmaceutical investment destination. Attractive conditions must be maintained both for the large pharmaceutical companies – which are well established in Switzerland, but for which the…
Switzerland Susanne Hoeppner, GM of Astellas Switzerland and board member of vips, discusses her key priorities, the culture of Swiss pharma, and the industry-wide push for faster approval times. Ms. Hoeppner, in addition to your role as general manager of Astellas, we understand you also have leadership role within the industry…
Switzerland Not all impactful innovation involves the development of new chemical or biological entities, and the value of such innovation must be recognized in pricing processes argues Gebro Pharma Switzerland CEO Marcel Plattner. We understand you serve as the head of the executive committee for market access and pricing within the…
Switzerland Walter P. Hölzle, president of vips, discusses the current priorities of the association, the importance of innovation, and the challenges of the current pricing system. While growth is close to zero for many pharmaceutical markets in Europe, Swiss pharma spending increased 4.5 percent in 2015. What would you identify as…
See our Cookie Privacy Policy Here